The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
FOOTPATH: NAPOLI versus sequential NAPOLI and mFOLFOX6 in mPDAC
Benedikt Westphalen, MD, PhD, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany, discusses the trial design of the Phase II FOOTPATH trial (NCT03487016), which compared gemcitabine with nab-paclitaxel, the NAPOLI regimen, and a sequence of NAPOLI and mFOLFOX6 in patients with metastatic pancreatic cancer (mPDAC). Despite the improvement in progression-free survival in patients receiving sequential therapy, it was not statistically significant. Safety was additionally improved in the sequential therapy arm. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
